Current CDDT processes, despite continual improvements, still rely on dissolvable coatings or hydrophilic matrix processes to deliver medication over a period of time. Coatings are only effective when they remain intact, causing a potential risk to the patient when cracks or breaks occur in a pill. Hydrophilic matrices, though more effective than traditional coatings, are created from an estimation of stomach acids and other fluids to break down the matrix, and their effectiveness is entirely dependent on each patient’s body matching these same estimates. Because no two patients are the same, even the most advanced time-release medications can cause potential spikes of toxicity or decreased bioavailability in different patients.

Crown Marketing Pharmaceuticals seeks to change that process entirely, providing for a more sustained and sustainable release of medication in each individual patient through our patented technology. Our process allows for the potential of a true 24-hour sustained-release product without the excessive overhead of chemical remanufacturing for matrix process medications, and without the risks associated with cracked or broken pill coatings.

VALUE PROPOSITION:

• Crown Marketing Pharmaceuticals realized the weaknesses and has built a better mousetrap.
  
  
• Crown Marketing Pharmaceuticals purports to have the “most advanced, yet elegantly simple approach to Controlled Drug Delivery.” The company’s CDDT (Controlled Drug Delivery Technology) is a patented delivery system built upon mathematically programming the rate of diffusion to deliver medications over a specified period of time.
  
  
• The CDDT promises precise targeting and more therapeutic benefits, potentially leading to decreased dosages, reduced side effects and a means to breathe life into the cash cows that typically contract by at least 50 percent upon patent expiration.
  
  
• CWNM’s technology is ideally suited for the formulation of prescriptions, nutraceuticals, and over-the-counter drugs. CWNM announced that its pharmaceutical technology will be focused on assisting pharmaceutical companies in their lifecycle management strategies to extend CWNM’s patent life for blockbuster drugs. With fewer products in the pipeline and blockbuster drugs edging towards the patent cliff, strategies that can extend the commercial life of mature brands are critical to bio-pharmaceutical companies today. Used properly, Lifecycle Management strategies can add several additional years of patent protection and billions of dollars of revenue for mature brands.
  
  
• CWNM also recently announced it is in discussions to grant non-exclusive licenses of its Controlled Drug Delivery Technology (CDDT) to nutraceutical and supplement companies. CWNM and its patented technology are a good fit with nutraceuticals in that it can increase the bio-availability of many of the compounds currently in use. The key is that CWNM’s technology has the ability to control the release with respect to amount dosed and the amount of time it is released into the body. This technology will give Nutraceutical companies the ability to differentiate themselves from the competition, and thereby increase their sales and margins.
  
  
• The nutraceutical industry is growing very rapidly as health conscious individuals look to natural and homeopathic remedies for their ailments.
  
  
• Crown’s platform is demonstrating a far superior spectrum and reliability of pharmacokinetic profiles. Crown’s technology is based on the observation that a device coated with an impervious membrane, with one or more orifices and of a defined geometry, releases molecules in an organized, predictable, and controllable manner utilizing compound-specific chemical potential energy along gradients.
  
  
• Crown has validated its technology through in vitro and in vivo experiments demonstrating the ability to generate nearly-constant and controlled concentrations of drug at the orifice over a selected period of time.